Moving from Promise to Practice in the Clinic

Trials by Therapeutic Area

Phase 3 ECHELON-2 trial for frontline treatment of mature T-cell lymphomas (also known as peripheral T-cell lymphoma) comparing brentuximab vedotin plus CHP with the standard-of-care CHOP. Enrollment in Study #SGN35-014 is complete. Learn more

Phase 1/2 CheckMate 436 trial for relapsed/refractory non-Hodgkin lymphomas with CD30 expression. Study #CA209-436 is currently recruiting participants. Learn more

Phase 3 CheckMate 812 trial for relapsed/refractory Hodgkin lymphoma evaluating brentuximab vedotin in combination with nivolumab. Study #CA209-812 is currently recruiting participants. Learn more

Phase 2 trial for frontline treatment of Hodgkin lymphoma in patients age 60 and above evaluating brentuximab vedotin as a single agent and in combination with other agents. Study #SGN35-015 is currently recruiting participants. Learn More

Phase 1/2 trial of brentuximab vedotin in combination with nivolumab. Study #SGN35-025 is ongoing, not recruiting participants. Learn More

Phase 2 CheckMate 744 trial for relapsed/refractory classical Hodgkin lymphoma in combination with nivolumab. Study #CA209-744 is currently recruiting participants. Learn more

Phase 3 EV-301 trial evaluating enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer. Study #7465-CL0-301. Learn more

Phase 2 EV-201 trial evaluating enfortumab vedotin for locally advanced or metastatic urothelial bladder cancer. Enrollment is complete for study #SGN22E-001. Learn more 

Phase 1b EV-103 trial evaluating enfortumab vedotin for first-line treatment of urothelial bladder cancer combined with checkpoint inhibitor therapy. Study #SGN22E-002 is currently recruiting participants. Learn more

Phase 2 innovaTV 204 trial evaluating tisotumab vedotin for patients with previously treated, recurrent or metastatic cervical cancer. Study #GCT1015-04 is currently recruiting participants. Learn more

Phase 2 innovaTV 207 trial evaluating tisotumab vedotin in multiple solid tumors. Study #SGNTV-001 is currently recruiting participants. Learn more

Phase 1 trial evaluating SEA-CD40 for advanced solid tumors and lymphoma. Study #SGNS40-001 is currently recruiting participants. Learn more

Phase 1 trial evaluating SGN-2FF in advanced solid tumors. Study #SGN2FF-001 is currently recruiting participants. Learn more

HER2CLIMB pivotal phase 2 trial of tucatinib vs placebo in combination with capecitabine and trastuzumab in patients with HER2+ breast carcinoma. Study ONT-380-206 is currently recruiting participants. Learn more

Phase 2 trial in locally-advanced or metastatic triple-negative breast cancer, evaluating ladiratuzumab vedotin in combination with pembrolizumab. Study #SGNLVA-002 is currently recruiting participants. Learn more

Phase 2 I-SPY 2 trial for HER2-negative breast cancer. Study #097517 is currently recruiting participants. Learn more

Phase 1b/2 trial of multiple immunotherapy-based treatment combinations in metastatic triple-negative breast cancer. Study #CO40115 is currently recruiting participants. Learn more

Phase 1 trial evaluating ladiratuzumab vedotin as a single agent for LIV-1-positive metastatic breast cancer. Study #SGNLVA-001 is currently recruiting participants. Learn more

Phase 1 trial evaluating SGN-CD48A in relapsed/refractory multiple myeloma. Study #SGN48-001 is currently recruiting patients. Learn More

Trials by Program

Phase 3 ECHELON-2 trial of frontline treatment for mature T-cell lymphomas (also known as peripheral T-cell lymphoma) comparing brentuximab vedotin plus CHP with the standard-of-care CHOP. Enrollment in Study #SGN35-014 is complete. Learn more

Phase 3 CheckMate 812 trial of brentuximab vedotin in combination with nivolumab for relapsed/refractory Hodgkin lymphoma. Study #CA209-812 is currently recruiting participants. Learn more

Phase 2 trial for frontline treatment of Hodgkin lymphoma in patients age 60 and above evaluating brentuximab vedotin as a single agent and in combination with other agents. Study #SGN35-015 is currently recruiting participants. Learn more

Phase 2 CheckMate 744 trial for relapsed/refractory classical Hodgkin lymphoma in combination with nivolumab. Study #CA209-744 is currently recruiting participants. Learn more

Phase 1/2 trial of brentuximab vedotin in combination with nivolumab for relapsed/refractory Hodgkin lymphoma. Study #SGN35-025 is ongoing, not recruiting participants. Learn more

Phase 1/2 CheckMate 436 trial of brentuximab vedotin in combination with nivolumab for relapsed/refractory non-Hodgkin lymphomas with CD30 expression. Study #CA209-436 is currently recruiting participants. Learn more

Phase 3 EV-301 trial evaluating enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer. Study #7465-CL0-301. Learn more

Phase 2 EV-201 trial for locally advanced or metastatic urothelial bladder cancer. Enrollment is complete in study #SGN22E-001. Learn more

Phase 1b EV-103 trial for urothelial bladder cancer combined with checkpoint inhibitor therapy. Enrollment in study #SGN22E-002 is currently recruiting participants. Learn more

Phase 2 innovaTV 204 trial evaluating tisotumab vedotin for patients with previously treated, recurrent or metastatic cervical cancer. Study #GCT1015-04 is currently recruiting participants. Learn more

Phase 2 innovaTV 207 trial evaluating tisotumab vedotin in multiple solid tumors. Study #SGNTV-001 is currently recruiting participants. Learn more

HER2CLIMB pivotal phase 2 trial of tucatinib vs placebo in combination with capecitabine and trastuzumab in patients with HER2+ breast carcinoma. Study ONT-380-206 is currently recruiting participants. Learn more

Phase 2 I-SPY 2 trial for HER2-negative breast cancer. Study #097517 is currently recruiting participants. Learn more

Phase 2 trial in locally-advanced or metastatic triple-negative breast cancer, evaluating ladiratuzumab vedotin in combination with pembrolizumab. Study #SGNLVA-002 is currently recruiting participants. Learn more

Phase 1b/2 trial of multiple immunotherapy-based treatment combinations in metastatic triple-negative breast cancer. Study #CO40115 is currently recruiting participants. Learn more

Phase 1 trial evaluating ladiratuzumab vedotin as a single agent for LIV-1-positive metastatic breast cancer. Study #SGNLVA-001 is currently recruiting participants. Learn more

Phase 1 trial for advanced malignancies. Study #SGNS40-001 is currently recruiting participants. Learn more

Phase 1 trial evaluating SGN-CD48A in relapsed/refractory multiple myeloma. Study #SGN48-001 is currently recruiting patients. Learn More

Phase 1 trial of SGN-2FF in advanced solid tumors. Study #SGN2FF-001 is currently recruiting participants. Learn more